Cargando…

Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma

BACKGROUND: Drug resistance is a primary hindrance for the efficiency of chemotherapy against osteosarcoma. Although chemotherapy has improved the prognosis of osteosarcoma patients dramatically after introduction of neo-adjuvant therapy in the early 1980's, the outcome has since reached platea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Susa, Michiro, Iyer, Arun K, Ryu, Keinosuke, Hornicek, Francis J, Mankin, Henry, Amiji, Mansoor M, Duan, Zhenfeng
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788581/ https://www.ncbi.nlm.nih.gov/pubmed/19917123 http://dx.doi.org/10.1186/1471-2407-9-399

Ejemplares similares

Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2010)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells
por: Zhang, Linlin, et al.
Publicado: (2015)

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
por: Duan, Zhenfeng, et al.
Publicado: (2014)

Nanoparticulate carriers for the treatment of coronary restenosis
por: Brito, Luis, et al.
Publicado: (2007)

MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer
por: Yang, Xiaoqian, et al.
Publicado: (2015)

ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) in Human Cancer Cell Lines
por: Duan, Zhenfeng, et al.
Publicado: (2009)

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer
por: Gao, Yan, et al.
Publicado: (2015)

MicroRNA Involvement in Osteosarcoma
por: Kobayashi, Eisuke, et al.
Publicado: (2012)

Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer
por: Milane, Lara, et al.
Publicado: (2011)

miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo
por: Duan, Zhenfeng, et al.
Publicado: (2016)

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
por: Liao, Yunfei, et al.
Publicado: (2017)

The role of extracelluar matrix in osteosarcoma progression and metastasis
por: Cui, Juncheng, et al.
Publicado: (2020)

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2017)

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2018)

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2018)

SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
por: Guo, Tao, et al.
Publicado: (2022)

Expression and Clinical Significance of High‐Mobility Group AT‐hook 2 (HMGA2) in Osteosarcoma
por: Cui, Juncheng, et al.
Publicado: (2022)

CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma
por: Gao, Yan, et al.
Publicado: (2015)

Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning
por: Milane, Lara, et al.
Publicado: (2011)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Thanindratarn, Pichaya, et al.
Publicado: (2021)

Rhabdomyosarcoma: Advances in Molecular and Cellular Biology
por: Sun, Xin, et al.
Publicado: (2015)

Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma
por: Feng, Wenlong, et al.
Publicado: (2020)

Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Correction to: Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats
por: Gao, Yan, et al.
Publicado: (2016)

Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
por: Sun, Ranran, et al.
Publicado: (2016)

Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression
por: Chen, Jiayi, et al.
Publicado: (2021)

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
por: Shen, Jacson K., et al.
Publicado: (2016)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

Potential carriers of chemotherapeutic drugs: matrix based nanoparticulate polymeric systems
por: Thukral, Dipti Kakkar, et al.
Publicado: (2014)

Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma
por: Li, Xiaoyang, et al.
Publicado: (2020)

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease
por: Kriegel, Christina, et al.
Publicado: (2011)

Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs
por: Choi, Jinhyang, et al.
Publicado: (2015)

NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance
por: Duan, Zhenfeng, et al.
Publicado: (2009)

Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers
por: Huang, Wenjing, et al.
Publicado: (2018)

Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers
por: Žigrayová, Dominika, et al.
Publicado: (2023)

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
por: Liu, Tang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_old327ks1qucs2rcbtrfto3f1i